Margetuximab|cas:1350624-75-7|西域试剂

Margetuximab,98.90%

产品编号：Bellancom-P99030| CAS NO：1350624-75-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99030		￥5200.00	杭州北京（现货）
Bellancom-P99030		￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Margetuximab

产品介绍

Margetuximab (MGAH22) 是一种嵌合抗 HER2 单克隆抗体，具有优化的 Fc 结构域，EC₅₀ 为 39.33 ng/mL。Margetuximab 可用于转移性 HER2 阳性乳腺癌研究。

生物活性

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.

体外研究

Margetuximab (MGAH22) enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	JIMT-1, MCF-7, ZR-75-1, SKBR-3, HT-29, SW750 and N87
Concentration:	0.001-1000 ng/mL
Incubation Time:	6 days
Result:	Enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant.

体内研究
(In Vivo)

Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 - 37 in mice model.
Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release.
Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile.
Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys.

	Male, IV (50 mg/kg)	Female, IV (50 mg/kg)
C_max (mg/mL)	1.62 ± 0.10	1.70 ± 0.14
AUC_0-¥ (mg·hour/mL)	294.1 ± 53.2	314.2 ± 31.3
T_1/2β (days)	9.3 ± 1.8	9.7 ± 1.1
Clearance (mL/hour)	0.43 ± 0.07	0.40 ± 0.04
V_SS (mL)	132 ± 2	127 ± 8

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

	Male, IV (50 mg/kg)	Female, IV (50 mg/kg)
C_max (mg/mL)	1.62 ± 0.10	1.70 ± 0.14
AUC_0-¥ (mg·hour/mL)	294.1 ± 53.2	314.2 ± 31.3
T_1/2β (days)	9.3 ± 1.8	9.7 ± 1.1
Clearance (mL/hour)	0.43 ± 0.07	0.40 ± 0.04
V_SS (mL)	132 ± 2	127 ± 8

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

	Male, IV (50 mg/kg)	Female, IV (50 mg/kg)
C_max (mg/mL)	1.62 ± 0.10	1.70 ± 0.14
AUC_0-¥ (mg·hour/mL)	294.1 ± 53.2	314.2 ± 31.3
T_1/2β (days)	9.3 ± 1.8	9.7 ± 1.1
Clearance (mL/hour)	0.43 ± 0.07	0.40 ± 0.04
V_SS (mL)	132 ± 2	127 ± 8